# A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome

> **NCT00508157** · PHASE4 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 125 (actual)

## Conditions studied

- Metabolic Syndrome
- Schizophrenia

## Interventions

- **DRUG:** Aripiprazole
- **DRUG:** Continued Antipsychotic (Risperidone or Quetiapine or Olanzapine)

## Key facts

- **NCT ID:** NCT00508157
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-11
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 125 (ACTUAL)
- **Why stopped:** Slow Accrual
- **Last updated:** 2013-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00508157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00508157, "A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00508157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*